Short Interest in PainReform Ltd. (NASDAQ:PRFX) Decreases By 13.3%

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 68,090 shares, a decrease of 13.3% from the February 26th total of 78,499 shares. Currently, 25.8% of the shares of the company are short sold. Based on an average daily trading volume, of 28,070 shares, the days-to-cover ratio is presently 2.4 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

PainReform Stock Down 9.1%

Shares of NASDAQ:PRFX opened at $1.89 on Tuesday. The firm’s 50 day moving average price is $3.03 and its 200-day moving average price is $4.54. PainReform has a twelve month low of $1.80 and a twelve month high of $17.95. The stock has a market capitalization of $756,000.00, a PE ratio of 0.00 and a beta of 0.55.

PainReform (NASDAQ:PRFX) last announced its earnings results on Thursday, March 26th. The company reported ($0.98) earnings per share (EPS) for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.